News - Oncology, Halaven


Current filters:


Popular Filters

Eisai’s breast cancer drug Halaven receives MAA in Europe

Eisai’s breast cancer drug Halaven receives MAA in Europe


The European Commission has issued Marketing Authorization Approval (MAA) for Halaven (eribulin) from…


Greater brand-drug adoption fuels Asia-Pacific breast cancer market


Due to an increasing uptake of branded drugs in Asia-Pacific (APAC), the region’s breast cancer therapeutics…

afatinibAsia-PacificBoehringer IngelheimEisaiHalavenKadcylaMarkets & MarketingneratinibOncologypalbociclibPerjetaPfizerPharmaceuticalResearchRoche

Eisai ties up with Newbridge to market Halaven in Middle East

Eisai ties up with Newbridge to market Halaven in Middle East


Japanese drug major Eisai says that its breast cancer drug Halaven (eribulin) will be marketed in selected…

EisaiHalavenMarkets & MarketingNewBridge PharmaceuticalsOncologyPharmaceuticalRest of the World

Eisai's new Belgium operation to help firm's globalization aims


Eisai EMEA (Europe, Middle East, Africa, Russia and Oceania), a division of Japanese drug major Eisai…

EisaiEuropeHalavenInovelonMarkets & MarketingOncologyPharmaceuticalRare diseases

Breast cancer drug Halaven now available in Russia


Japanese drug major Eisai (TYO: 4523) said this morning (September 12) that Halaven (eribulin) is now…

EisaiEuropeHalavenMarkets & MarketingOncologyPharmaceutical

More highlights from ASCO for: Eisai's Halaven; Boehringer's nintedanib; and Lilly's Alimta


Among further highlights from the ongoing American Society of Clinical Oncology (ASCO) meeting in Chicago,…

AlimtaBoehringer IngelheimEisaiHalavenLillynintedanibOncologyPharmaceuticalResearch

Eisai files for new Halaven indication; gets orphan status for lenvatinib in EU


Japanese drug major Eisai (TYO: 4523) has filed a Type II Variation application with the European Medicines…


Eisai joins trend to enter Russian pharma market, with Halaven launch


Japanese drug major Eisai (TYO; 4523, through its EMEA (Europe, Middle East and Africa) unit, has announced…

EisaiEuropeExaliefFycompaHalavenInovelonMarkets & MarketingNeurologicalOncologyPharmaceuticalZonegran

Growing patient population to drive Mexican breast cancer market


An expanding patient population will largely contribute to the growth of the market for treating breast…

AfinitorEisaiHalavenKadcylaMarkets & MarketingNovartisOncologyPerjetaPharmaceuticalRocheSouth Americatrastuzumab emtansine

Eisai expands in South Africa, filing for approval of Halaven and Fycompa


Japanese drug major Eisai (TYO: 4523) says it is expanding its operations into South Africa, with the…

EisaiFycompaHalavenMarkets & MarketingNeurologicalOncologyPharmaceuticalRegulationRest of the World

Eisai gets South Korean approval for breast cancer drug Halaven


The South Korean sales subsidiary of Japanese drug major Eisai (TYO: 4523) has received approval from…


Eisai enters deals with Valeant and Minophagen


The European subsidiary of Japanese drug major Eisai (TYO: 4523) and PharmaSwiss, a division of Canada-based…

bexaroteneEisaiHalavenLicensingMarkets & MarketingMinophagenOncologyPharmaceuticalValeant Pharmaceuticals

Eisai breast cancer drug still viewed as not cost effective by NICE


In a third rejection, the UK drug watchdog the National Institute for Health and clinical Excellence…


Added benefit of Eisai’s Halaven not proven, says Germany’s IQWiG


In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…


UK’s NICE rejects Eisai’s Halaven for advanced breast cancer


In a second negative from the UK’s National Institute for Health and Clinical Excellence, in final…


Back to top